UniQure Huntington's therapy does not reach statistical significance in trial
UniQure said its Huntington's treatment slowed disease progression by 44% but did not reach statistical significance in an ongoing early-to-mid-stage trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.